Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

This study examined the effects on incretin mimetics on vascular physiology in the prediabetic postprandial state.

Methods: Fifteen obese adults with prediabetes participated in a randomized, crossover, double-blinded trial comparing the postprandial effects of exenatide, saxagliptin, and placebo on peripheral vasodilation.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

In the crossover set-up each of the participants took both Exenatide and the comparison in turn, acting as their own control.

Resting and peak forearm blood flow (FBF) were measured via strain gauge venous occlusion plethysmography, and makers of vascular dysfunction were measured in plasma.

What Was Measured

The subject headings attached to it are Adamantane, Biomarkers, Blood Glucose, Dietary Fats, Dipeptides, Exenatide and Forearm.

The authors tagged it with the keywords endothelium, postprandial, prediabetes and vasodilation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide.

The publication is from 2020 (Metabolic syndrome and related disorders), a journal based in United States.

More context: the Exenatide compound page, all human trials.